AC Immune SA reported a net loss after taxes of CHF 15.9 million for the third quarter ended September 30, 2025, compared to a net income of CHF 5.5 million for the same period in 2024. The difference was mainly due to the recognition of a CHF 24.6 million milestone in Q3 2024 under a collaboration with Janssen Pharmaceuticals. The financial result, net was a CHF 0.3 million gain, compared to a CHF 1.8 million loss in the prior year period, primarily due to more stable foreign currency exchange differences. As of September 30, 2025, cash resources totaled CHF 108.5 million, expected to fund operations through the end of Q3 2027, excluding potential milestone income. During the period, the company reduced its workforce by around 30% and continued development of its Phase 2 active immunotherapy programs and small molecule therapeutics, with IND/CTA filings for NLRP3 and Tau-targeting compounds expected by year-end.